The role of adherence to antiretroviral therapy in the management of HIV infection

被引:73
作者
Conway, Brian [1 ]
机构
[1] Univ British Columbia, Fac Med, Dept Pharmacol & Therapeut, Downtown Infect Dis Clin, Vancouver, BC V6Z 2C7, Canada
关键词
adherence; antiretrovirals; directly observed therapy; HIV; ONCE-DAILY THERAPY; COMBINATION THERAPY; DAILY LAMIVUDINE; TENOFOVIR DF; CELL COUNT; EFAVIRENZ; REGIMEN; ADULTS; INTERVENTION; ZIDOVUDINE;
D O I
10.1097/QAI.0b013e3180600766
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Despite multiple studies demonstrating the relation between the success of highly active antiretroviral therapy (HAART) and adherence, inadequate adherence continues to be one of the most frequent reasons for poor treatment outcomes and/or lack of sustained treatment benefits. Interventions targeting patient-related social and psychologic barriers to adherence and issues related to mental health and substance abuse and access to health care may ameliorate their negative impact on adherence. Specific drug-related factors that influence adherence such as pill burden, dosing frequency, food requirements, and acute tolerability and safety concerns, however, are further issues that must be considered to optimize adherence. Fortunately, the availability of once-daily and coformulated agents with simple dosing requirements may help to improve adherence, and thereby make the difference between success and failure of HAART for some patients. A better understanding of adherence and its determinants and how to define specific goals in a given clinical setting are keys for clinicians to become more effective partners with patients in the achievement and maintenance of long-term virologic suppression and, more importantly, long-term health.
引用
收藏
页码:S14 / S18
页数:5
相关论文
共 46 条
[1]   Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates [J].
Bangsberg, DR ;
Porco, TC ;
Kagay, C ;
Charlebois, ED ;
Deeks, SG ;
Guzman, D ;
Clark, R ;
Moss, A .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (01) :162-165
[2]   'Simply forgot' is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence [J].
Barfod, T. S. ;
Sorensen, H. T. ;
Nielsen, H. ;
Rodkjaer, L. ;
Obel, N. .
HIV MEDICINE, 2006, 7 (05) :285-290
[3]   Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults [J].
Bartlett, JA ;
DeMasi, R ;
Quinn, J ;
Moxham, C ;
Rousseau, F .
AIDS, 2001, 15 (11) :1369-1377
[4]  
BASS D, 2002, 14 INT AIDS C
[5]   A systematic review of the associations between dose regimens and medication compliance [J].
Claxton, AJ ;
Cramer, J ;
Pierce, C .
CLINICAL THERAPEUTICS, 2001, 23 (08) :1296-1310
[6]  
COHEN C, 2005, 3 INT AIDS SOC C HIV
[7]   Directly observed therapy for the management of HIV-infected patients in a methadone program [J].
Conway, B ;
Prasad, J ;
Reynolds, R ;
Farley, J ;
Jones, M ;
Jutha, S ;
Smith, N ;
Mead, A ;
DeVlaming, S .
CLINICAL INFECTIOUS DISEASES, 2004, 38 :S402-S408
[8]   Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: A randomized equivalence trial [J].
DeJesus, E ;
McCarty, D ;
Farthing, CF ;
Shortino, DD ;
Grinsztejn, B ;
Thomas, DA ;
Schrader, SR ;
Castillo, SA ;
Sension, MG ;
Gough, K ;
Madison, SJ .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (03) :411-418
[9]   A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection [J].
Dybul, M ;
Nies-Kraske, E ;
Dewar, R ;
Maldarelli, F ;
Hallahan, CW ;
Daucher, M ;
Piscitelli, SC ;
Ehler, L ;
Weigand, A ;
Palmer, S ;
Metcalf, JA ;
Davey, RT ;
Kress, DMR ;
Powers, A ;
Beck, I ;
Frenkel, L ;
Baseler, M ;
Coffin, J ;
Fauci, AS .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (11) :1974-1982
[10]  
FISCHL M, 2001, 8 C RETR OPP INF